Renal cell carcinoma (advanced) - axitinib [ID518]: evaluation report

Table of Contents

01. NICE's response to comments on the Appraisal Consultation Document (ACD)

02. [Consultee/Commentator] comments on the ACD - Pfizer

03. [Consultee/Commentator] comments on the ACD - Kidney Cancer UK

04. [Consultee/Commentator] comments on the ACD - Royal College of Physicians

05. Clinical expert comments on the ACD - Hawkins

06. Public comments on the ACD received via the NICE website

07. ERG Response following specific questions from NICE provided by Kleijnen Systematic Reviews



Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.


This page was last updated: 11 December 2014